Compare SCHL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | AUTL |
|---|---|---|
| Founded | 1920 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 596.2M |
| IPO Year | 1995 | 2025 |
| Metric | SCHL | AUTL |
|---|---|---|
| Price | $34.91 | $1.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $8.50 |
| AVG Volume (30 Days) | 258.0K | ★ 2.2M |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 3442.86 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $1,487,100,000.00 | $10,120,000.00 |
| Revenue This Year | $1.88 | $80.32 |
| Revenue Next Year | $4.05 | $53.96 |
| P/E Ratio | $14.96 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $22.69 | $1.18 |
| 52 Week High | $48.07 | $2.58 |
| Indicator | SCHL | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 28.93 | 41.61 |
| Support Level | $32.81 | $1.37 |
| Resistance Level | $36.00 | $2.07 |
| Average True Range (ATR) | 1.53 | 0.10 |
| MACD | -0.29 | -0.08 |
| Stochastic Oscillator | 11.37 | 15.00 |
Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.